Literature DB >> 29674193

Does induction of labour in nulliparous hypertensive women result in vaginal birth? - A descriptive study utilising birth registry data.

Charlene Eliza Thornton1, Hannah Grace Dahlen2, Annemarie Hennessy3.   

Abstract

BACKGROUND: Induction of labour (IOL) is a common procedure yet we have little information on the efficacy of the process for women with a hypertensive disorder of pregnancy (HDP).
OBJECTIVE: To describe the birth type and associated factors in nulliparous HDP women undergoing an induction of labour. STUDY
DESIGN: Statutorily collected datasets on every birth and hospital admission which occurred in the state of NSW Australia between the years 2000-2011 were analysed. Hypertensive women were compared to normotensive women.
RESULTS: Of the nulliparous women, 9.9% had a HDP. IOL for HDP women were 56.2% in a cohort of 447 558 women. The AOR for a woman with a HDP undergoing an IOL resulting in a vaginal delivery when compared to a normotensive woman is 0.86 (95% CI 0.83-0.88). Prior to 33 weeks, the lowest perinatal mortality rates (PMR) are seen in women who undergo elective caesarean section (C/S). For women with preeclampsia (PE), lower PMR are seen in women who undergo IOL.
CONCLUSION: For women with PE and SPE, IOL resulted in lower rates of vaginal delivery than spontaneous labour when compared to normotensive women who also underwent IOL. Women with PE at ≥33 weeks who underwent IOL had the lowest PMR.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Chronic hypertension; Gestational hypertension; Induction of labour; Preeclampsia; Pregnancy hypertension

Mesh:

Year:  2018        PMID: 29674193     DOI: 10.1016/j.preghy.2018.01.010

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  1 in total

1.  Influence of Preeclampsia on Induction of Labor at Term: A Cohort Study.

Authors:  Jutta Pretscher; Christel Weiss; Ulf Dammer; Florian Stumpfe; Florian Faschingbauer; Matthias W Beckmann; Sven Kehl
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.